Sionna Therapeutics, Inc. SION 深 滬
已收盤 12-24 16:00:00 美东时间
44.025
+0.585
+1.35%
華盛通- 最 高44.70
- 今 開44.03
- 成交量 15.55万股
- 最 低 43.815
- 昨 收 43.44
- 總市值 19.43亿
- 52周最高 45.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 7.255
- 委 比 -52.52%
- 總股本 4413.98万
- 歷史最高 45.00
- 量 比 0.26
- 振 幅 2.04%
- 歷史最低 7.255
- 每 手 1
- 風險率 10.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
12-24 11:17
LifeSci Capital Initiates Coverage On Sionna Therapeutics with Outperform Rating, Announces Price Target of $60
LifeSci Capital analyst Cory Jubinville initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Outperform rating and announces Price Target of $60.
12-24 00:09
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
12-02 09:50
RBC Capital Downgrades Sionna Therapeutics to Underperform, Maintains Price Target to $24
RBC Capital analyst Brian Abrahams downgrades Sionna Therapeutics (NASDAQ:SION) from Sector Perform to Underperform and maintains the price target from $24 to $24.
12-01 22:27
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
11-20 10:28
BTIG Initiates Coverage On Sionna Therapeutics with Buy Rating, Announces Price Target of $50
BTIG analyst Kambiz Yazdi initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Buy rating and announces Price Target of $50.
11-19 18:14
Sionna Therapeutics Q3 EPS $(0.46) Beats $(0.49) Estimate
Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.49) by 6.69 percent. This is a 91.89 percent increase over losses of $(5.67) per share
11-05 20:11
Metsera Receives Unsolicited Proposal from Novo Nordisk
Metsera Declares Novo Nordisk Proposal "Superior" Novo Nordisk Proposal Values Metsera at up to $77.75 per Share, a Total of Approximately $9 Billion Pursuant to Pfizer Merger Agreement, Met...
10-30 19:07
Lilly to Acquire Adverum Biotechnologies
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition ali...
10-24 20:30
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
Sionna Therapeutics announced data at the 2025 North American Cystic Fibrosis Conference showing that its first-in-class NBD1 stabilizers, SION-719 and SION-451, were generally well-tolerated in Phase 1 trials and exceeded pharmacokinetic targets. New preclinical data revealed that these stabilizers restored the half-life of the F508del-CFTR protein to wild-type levels, potentially offering a significant advancement in CF treatment. The company i...
10-24 17:15
